Skip to main content
. Author manuscript; available in PMC: 2019 Feb 15.
Published in final edited form as: Cancer. 2018 Jan 8;124(4):775–784. doi: 10.1002/cncr.31077

Figure 2. Overall survival among patients 80 years and older with stage III lung cancer treated with concurrent chemoradiation, definitive radiation alone, and those who did not receive therapy, excluding patients who died within six months.

Figure 2

Overall survival (OS) was calculated as time from diagnosis to time to death. Patients who died within 6 months of diagnosis were excluded from analysis. The number at risk is delineated above the x axis at each time point. Kaplan-Meier estimates for median OS were 13.2 months (95%CI: 12.7–14), 9.6 months (95%CI: 9.0–10.2), and 7.2 months (95%CI: 6.1–8.3) for patients treated with concurrent chemoradiation, definitive radiation alone, and no treatment respectively (p<0.01). 5-year OS estimates were compared using log-rank tests, with rates of 11.2% (95%CI: 9.7–12.7), 6.5% (95%CI: 4.7–8.6), and 4.3% (95%CI: 3.3–5.5) for patients treated with concurrent chemoradiation, definitive radiation alone, and no treatment respectively (p<0.01).